Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Birendra Kumar Sah has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Li

    Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    12 shared publications
  • Chen Li

    Shanghai Jiao Tong University School of Medicine

    11 shared publications
  • Min Yan

    Ruijin Hospital Shanghai Jiao Tong University School of Medicine

    10 shared publications
  • Zhenggang Zhu

    Shanghai Jiao Tong University School of Medicine

    7 shared publications
  • Chen Li

    Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    6 shared publications
  • Fei Yuan

    Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    6 shared publications

Latest Publications

  • Open Access

    Stage-specific overall survival with complete five-year follow-up after D2 gastrectomy for gastric cancer at a referral hospital in Shanghai, China: a reference for comparing hospitals

    by Birendra Kumar Sah, Danping Gu, Jian Li, Erzhen Chen

    Background: Comparing long-term outcomes of gastric cancer surgery between hospitals requires a common reference. Risk-adjusted benchmarks depend on the model and population used to build them and are difficult for another hospital to reproduce. TNM stage is a prognostic classification already recorded for every resected gastric cancer. We report unadjusted stage-specific overall survival from a consecutive cohort with complete follow-up as reference data and propose a minimal dataset for producing comparable figures elsewhere. Methods: The cohort comprised 690 consecutive eligible patients who underwent curative-intent D2 gastrectomy for stage I to III adenocarcinoma at Ruijin Hospital, Shanghai, in 2019. All operations were performed by eight experienced, high-volume consultant surgeons. Stage followed the AJCC 8th edition: pTNM after upfront surgery (n = 570) and ypTNM after neoadjuvant chemotherapy (n = 120). Overall survival was estimated by the Kaplan-Meier method without adjustment. Results: There were 199 deaths, 181 within five years. Every survivor was followed for at least 68.1 months. After upfront surgery, five-year overall survival was 95.0% (95% CI 91.4 to 97.1) for stage I, 83.8% (76.5 to 89.0) for stage II and 56.5% (49.2 to 63.1) for stage III, and was 95.0% in IA and 95.2% in IB, falling to 26.7% in IIIC. After neoadjuvant chemotherapy, five-year survival was 78.6%, 61.9% and 31.3% for ypStage I, II and III. Pooling pTNM and ypTNM lowered stage III five-year survival to 50.2%. The proposed minimal dataset has 16 items, 13 of them recorded during the admission for gastrectomy. Conclusions: These figures are intended as a reference for comparing hospitals rather than as a standard of care. We propose 16 items, most of them routinely recorded, from which another hospital can produce the same table and compare its results by stage.

  • Open Access

    Immortal time bias reproduces the reported survival benefit of conversion surgery in stage IV gastric cancer: a simulation study

    by Birendra Kumar Sah, Chen Li, Jian Li, Zhenggang Zhu

    Background Conversion surgery for stage IV gastric cancer is supported by a pooled overall survival hazard ratio of 0.36 (95% confidence interval 0.32-0.40) and, in the largest international cohort, median survival of 36.7 versus 12.5-13.8 months on chemotherapy. Survival is measured from diagnosis; the median diagnosis-to-gastrectomy interval is 124 days, which patients must survive to be counted surgical. Methods We simulated cohorts of 3,177 stage IV gastric cancer patients from published parameters: background median survival 14.5 months; median diagnosis-to-surgery interval 124 days (category-specific 92-174 days). Surgery had no effect (true hazard ratio 1.00 by construction). Data were analysed as the literature analyses them (exposure fixed at baseline, follow-up from diagnosis), and by time-varying Cox and landmark analysis. Confounding by indication was added in a second scenario. Results Under immortal time bias alone the naive analysis returned a hazard ratio of 0.794 (95% simulation interval 0.743-0.851), median survival 16.8 versus 12.8 months. Time-varying Cox recovered 1.000 and landmark analysis 1.000-1.004. Bias scaled with the interval: 0.849 at 92 days, 0.715 at 174 days. Adding confounding, the naive estimate fell to 0.601 (0.560-0.644) at strength 0.5 and 0.356 (0.323-0.385) at strength 1.5, overlapping the published estimate; median survival 21.9 versus 8.7 months. Correcting immortal time alone left residual bias (hazard ratio 0.439). Conclusions The reported survival advantage of conversion surgery is reproducible where the operation does nothing; published estimates cannot distinguish benefit from bias. Resolving this requires individual patient data analysed with methods that assign person-time correctly, or completion of JCOG2301.

  • Open Access

    The Surgical Assessment and Healthcare (SAH) Index: A Risk-Adjusted Framework for Surgeon-Level Quality Audit in Gastric Cancer

    by Birendra Kumar Sah, Danping Gu, Chenjie Dong, Jian Li, Minmin Zhang, Rui Jin, Xiaoyang Li, Erzhen Chen

    Background: Gastric cancer outcomes vary, yet surgeon-level variation is rarely quantified after risk adjustment. We tested whether surgeon identity independently predicts survival and developed and internally validated a risk-adjusted, surgeon-level framework for auditing surgical treatment quality, the Surgical Assessment and Healthcare (SAH) Index. Study Design: Single-institution retrospective cohort study (Ruijin Hospital, Shanghai Jiao Tong University; NCT07180966 ) of 690 patients undergoing curative-intent resection for pStage I–III gastric adenocarcinoma in 2019 by eight consultant surgeons. Overall survival was modeled by multivariable Cox regression (199 events), with complete-case, stage-stratified, and upfront-surgery sensitivity models. The SAH Index expressed surgeon × stage observed-to-expected ratios for 5-year mortality and major morbidity (Clavien–Dindo ≥ IIIa), with flags from Poisson intervals. Results: Independent predictors were stage (HR 2.969/step), age (HR 1.031/year), and non-distal gastrectomy (HR 1.480; all p ≤ .008). Surgeon identity was marginally associated with survival (Wald p = .047, likelihood-ratio p = .074): S6 (HR 2.167, 95% CI 1.288–3.647) and S8 (HR 1.968, 1.033–3.749) carried roughly double the reference hazard; S6 persisted across sensitivity, bootstrap, and propensity-score analyses. S8 attenuated on resampling. Stage-stratified models localized these (S6, Stage II; S8, Stage III). Both risk models were well calibrated. Benchmarking flagged one survival-outlier cell (S6, Stage II); no morbidity outlier was detectable, given few complication events and a weakly discriminating morbidity model. Conclusions: A single surgeon showed a persistent risk-adjusted survival signal, localized to one stage and without a morbidity excess; the marginal overall association is best read as this one localized outlier rather than broad between-surgeon variation. The SAH Index is presented as a development-stage, internally validated framework for surgeon-level audit; prospective, multi-center validation is the planned next phase.

  • Open Access

    Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial

    by Birendra Kumar Sah, Zhenjia Yu, Benyan Zhang, Fei Yuan, Huan Zhang, Jian Li, Tao Ma, Min Shi, Zhenglun Zhu, Yanan Zheng, et al.


  • Open Access

    Case Report: A Novel Reconstruction Method (Itihaas’s Anastomosis) for Proximal Gastrectomy

    by Birendra Kumar Sah, Zhenjia Yu, Chen Li, Zhenggang Zhu

    This study introduces a novel reconstruction method (Itihaas’s Anastomosis) for the upper gastrointestinal (UGI) tract following proximal gastrectomy, designed to mitigate the severity of acid reflux syndrome, a frequent postoperative complication. The procedure comprises three side-to-side anastomoses: esophago-gastrostomy, gastro-jejunostomy, and jejuno-jejunostomy. The esophago-gastrostomy anastomosis aims to prevent direct reflux of gastric contents into the esophagus by creating a fundus-like structure, which also facilitates future endoscopic procedures. The gastro-jejunostomy reduces acid reflux by diverting gastric acid to the jejunum for further neutralization, while the jejuno-jejunostomy prevents bile and pancreatic juice reflux into the stomach. A 75-year-old male with adenocarcinoma of the upper stomach underwent this surgical procedure. Postoperative outcomes showed no major complications, with smooth oral contrast passage and no evidence of anastomotic leaks. The patient was discharged after resuming consumption of semi-solid food and experienced no signs of reflux. Itihaas’s Anastomosis represents a novel technical approach that theoretically may reduce acid reflux following proximal gastrectomy. Initial case experience suggests technical feasibility, though all claimed benefits remain theoretical without objective validation. Long-term outcomes, anti-reflux efficacy, and comparative effectiveness require validation through systematic case series with objective assessments.

  • Open Access

    FLOT versus SOX Neoadjuvant Chemotherapy: First Prospective Survival Comparison in Locally Advanced Gastric Cancer

    by Birendra Kumar Sah, Chen Li, Zhenggang Zhu

    Background: Both FLOT and SOX neoadjuvant regimens are widely used for locally advanced gastric cancer; however, direct head-to-head survival data to guide optimal treatment selection are lacking. Methods: We conducted an open-label, randomized, phase 2 trial ( NCT03636893 ) at a single center in China. Patients with locally advanced gastric cancer (cT3-4b, cN1-3, cM0) were randomized to receive neoadjuvant FLOT (four cycles) or SOX (three cycles) before D2 gastrectomy. We report the long-term survival outcomes with 5-year follow-up in 74 randomized patients through May 2025. Results: The first prospective comparison demonstrated remarkable outcomes for both regimens. With median follow-up of 65.7 months, median overall survival exceeded 5 years in both groups: 61.5 months (95% CI: not reached) for FLOT versus 67.8 months (95% CI: 25.7-109.9) for SOX, with no significant difference (HR 1.101, 95% CI: 0.595-2.036, p=0.759). Disease-free survival was equivalent (23.0 vs 25.5 months, HR 1.060, p=0.842). Clinicopathological factors proved to be more prognostic than regimen choice: complete/subtotal tumor regression achieved 80.5-month survival versus 47.6 months for partial response (p=0.017), whereas gastrectomy type emerged as the strongest independent predictor (HR 3.619 for total vs. partial gastrectomy, p=0.010). Both regimens demonstrated favorable safety profiles with manageable toxicity. Conclusions: This study establishes equivalent long-term survival between the FLOT and SOX regimens. With both achieving 5-year survival, treatment selection should prioritize patient factors, institutional experience, and practical considerations, rather than expected survival differences. Optimizing the pathological response and surgical approach appears more critical than specific regimen choice. Funding: This research received no specific grant funding.

  • Open Access

    Case Report: Itihaas's Omega Anastomosis for Distal Gastrectomy

    by Birendra Kumar, Yu Zhenjia, Li Chen, Zhu Zhenggang

    This study introduces a novel reconstruction method for the upper gastrointestinal (UGI) tract following distal gastrectomy, called Itihaas's Omega Anastomosis. This technique is designed to preserve the natural anatomical connection between the stomach and duodenum. It serves as an alternative anastomotic approach in cases where Billroth I (gastroduodenostomy) cannot be performed due to tension or other technical limitations. Itihaas's Omega Anastomosis also facilitates access for endoscopic retrograde cholangiopancreatography (ERCP) and can be considered a complementary option to the traditional Billroth II (gastrojejunostomy) with Braun (jejunojejunostomy) anastomosis. The technique involves three side-to-side anastomoses: gastrojejunostomy, jejunojejunostomy, and jejunoduodenostomy. The inclusion of the jejunoduodenostomy establishes a direct route for food to pass from the stomach to both the duodenum and jejunum, potentially helping to mitigate dumping syndrome. Additionally, it provides a viable route for ERCP when necessary. The gastrojejunostomy allows immediate passage to the jejunum, minimizing bile reflux, while also diverting gastric acid for neutralization, thereby reducing acid reflux. The jejunojejunostomy further prevents reflux of bile and pancreatic juices into the stomach. This technique was performed on two female patients, aged 67 and 71, who had adenocarcinoma of the gastric antrum. Postoperative outcomes were favorable, with no major complications. Both patients exhibited smooth oral contrast passage with no signs of anastomotic leakage. They resumed semi-solid diets successfully and were discharged without experiencing reflux symptoms. Itihaas's Omega Anastomosis shows promise in reducing acid reflux and enhancing postoperative quality of life for patients undergoing distal gastrectomy. By preserving natural anatomy and function while minimizing reflux, it may offer advantages over conventional anastomoses. However, further studies are needed to validate these preliminary findings and compare long-term outcomes with existing techniques.

  • Open Access

    Neoadjuvant chemotherapy or adjuvant chemotherapy is similarly beneficial for five-year overall survival in locally advanced gastric cancer patients

    by Sah Birendra Kumar, Yu Zhenjia, Lu Sheng, Zheng Yanan, Zhu Zhenglun, Li Jian, Li Chen, Yan Min, Zhu Zhenggang

    Background: Different types of neoadjuvant chemotherapy regimens have been compared for gastric cancer, mostly in terms of radiological downgrading or pathological tumor regression; however, no large-scale multicenter randomized controlled trial (RCT) has conducted a head-to-head comparison of the overall survival rate between perioperative or neoadjuvant chemotherapy(NAC) and postoperative or adjuvant chemotherapy(AC). We explored whether the five-year overall survival rate was greater in patients who received perioperative chemotherapy plus surgery than in those who underwent surgery first and then underwent postoperative chemotherapy. Methods: Altogether, 77 patients with a clinical diagnosis of cTNM stage III were included. Five-year overall survival (OS) rates were compared between patients who underwent neoadjuvant chemotherapy plus surgery (NAC) and those who underwent surgery first plus adjuvant chemotherapy (AC). Propensity score matching was used to adjust for disparity between the two groups. A Kaplan-Meier plot was created for survival analysis, and the log-rank method was used to compare the differences in OS. Results: A total of 34 patients were in the NAC and 43 patients were in the AC group, respectively. There was no significant difference in age (median, 64 vs. 66 years), cTNM staging, or extent of gastrectomy between the two groups (p0.05). There was no significant difference in the severity of postoperative complications between the two groups (p>0.05). Conclusions: There was no significant difference in the five-year overall survival rate between patients who underwent perioperative chemotherapy plus surgery and those who underwent surgery plus postoperative chemotherapy alone. A well-controlled prospective study is necessary to confirm whether perioperative chemotherapy is superior to postoperative chemotherapy in patients with GC.


  • Open Access

    Evaluating the Role of Neoadjuvant and Adjuvant Chemotherapy in Gastric Cancer: A Retrospective Study and Future Directions

    by Birendra Kumar Sah, Zhen Jia Yu, Sheng Lu, Yanan Zheng, Zhenglun Zhu, Jian Li, Chen Li, Min Yan, Zhenggang Zhu

    Background Different types of neoadjuvant chemotherapy regimens have been compared for gastric cancer, mostly in terms of radiological downgrading or pathological tumor regression; however, no large-scale multicenter randomized controlled trial (RCT) has conducted a head-to-head comparison of the overall survival rate between perioperative or neoadjuvant chemotherapy(NAC) and postoperative or adjuvant chemotherapy(AC). We explored whether the five-year overall survival rate was greater in patients who received perioperative chemotherapy plus surgery than in those who underwent surgery first and then underwent postoperative chemotherapy. Methods Altogether, 77 patients with a clinical diagnosis of cTNM stage III were included. Five-year overall survival (OS) rates were compared between patients who underwent neoadjuvant chemotherapy plus surgery (NAC) and those who underwent surgery first plus adjuvant chemotherapy (AC). Propensity score matching was used to adjust for disparity between the two groups. A Kaplan-Meier plot was created for survival analysis, and the log-rank method was used to compare the differences in OS. Results A total of 34 patients were in the NAC and 43 patients were in the AC group, respectively. There was no significant difference in age (median, 64 vs. 66 years), cTNM staging, or extent of gastrectomy between the two groups (p < 0.05). The median follow-up time was 58 months (range: 53–65 months). The five-year overall survival (OS) rates for patients in the NAC and AC groups were 61.8% and 73.5%, respectively. There was no significant difference between the two groups in the five-year overall survival rates (p > 0.05). There was no significant difference in the severity of postoperative complications between the two groups (p > 0.05). Conclusions There was no significant difference in the five-year overall survival rate between patients who underwent perioperative chemotherapy plus surgery and those who underwent surgery plus postoperative chemotherapy alone. A well-controlled prospective study is necessary to confirm whether perioperative chemotherapy is superior to postoperative chemotherapy in patients with GC.

  • Open Access

    Predictive factors and diagnostic significance of CT findings for anastomotic leak after gastric cancer surgery: A retrospective analysis

    by Birendra Kumar Sah, Yang Zhang, Jian Li, Chen Li, Huan Zhang, Min Yan, Zheng Gang Zhu

    Background: Anastomotic leak following radical gastrectomy poses a significant risk to patients. Despite previous studies, effective methods for diagnosing anastomotic leaks after gastric cancer surgery remain elusive. In this study, we aimed to assess the overall burden of anastomotic leaks and investigate diagnostic factors, particularly radiological signs on postoperative computed tomography (CT), that may facilitate early detection.Methods: We included a total of 70 gastric cancer patients who underwent curative gastrectomy and underwent CT examination post‐surgery. Among them, 35 patients with anastomotic leak were matched with 35 patients without anastomotic leak. We compared the rates of various types of postoperative complications between the two groups and conducted univariate and multivariate analyses to identify predictive variables for postoperative diagnosis.Results: Patients with anastomotic leaks experienced significantly longer postoperative hospital stays and higher overall expenditures (p < 0.001). Logistic regression analysis revealed that extraluminal gas at the anastomosis site, fever (T ≥ 38.5°C), and neutrophilia (NE ≥ 78%) on postoperative days 4–7 were independent diagnostic factors for anastomotic leaks (p < 0.05).Conclusions: The diagnostic factors identified in this study offer valuable insights into early detection of anastomotic leaks. We recommend early CT examination for patients exhibiting consistent fever and neutrophilia between postoperative days 4 and 7 following gastric cancer surgery.